Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common Stock Valuation Ratios (Price Multiples)

Beginner level

Current Valuation Ratios

Regeneron Pharmaceuticals Inc., current price multiples

Microsoft Excel LibreOffice Calc
Regeneron Pharmaceuticals Inc. Abbott Laboratories AbbVie Inc. Amgen Inc. Biogen Inc. Bristol-Myers Squibb Co. Eli Lilly & Co. Gilead Sciences Inc. Illumina Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Vertex Pharmaceuticals Inc. Zoetis Inc. Pharmaceuticals & Biotechnology Health Care
Selected Financial Data
Current share price (P) $583.14
No. shares of common stock outstanding 106,392,394
Growth rate (g) 21.71%
 
Earnings per share (EPS) $19.89
Next year expected EPS $24.20
Operating profit per share $20.77
Sales per share $73.91
Book value per share (BVPS) $104.23
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 29.32 51.88 18.88 17.23 7.23 39.83 16.42 14.10 46.81 25.13 20.21 12.91 48.81 50.68 21.22 24.33
Price to next year expected earnings 24.09 54.01 15.08 15.13 5.43 41.53 14.26 11.14 37.89 30.28 20.93 12.26 44.43 36.19 19.06 22.10
Price-earnings-growth (PEG) 1.35 0.75 1.24 0.22 1.08 0.53 1.99 2.45 4.96 1.27 1.88 2.41
Price to operating profit (P/OP) 28.08 42.21 11.46 13.97 6.04 23.16 27.46 17.71 47.62 19.18 17.15 15.94 47.96 38.65 18.92 21.29
Price to sales (P/S) 7.89 6.00 4.47 6.09 2.96 5.24 6.12 3.43 13.24 4.63 4.25 4.06 13.80 12.14 5.07 4.10
Price to book value (P/BV) 5.59 6.15 13.97 3.19 2.65 52.39 3.37 10.17 6.39 7.68 3.33 9.44 28.07 6.42 5.80

Based on: 10-K (filing date: 2020-02-07).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Regeneron Pharmaceuticals Inc., historical price multiples

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Price to earnings (P/E) 19.86 18.17 28.99 42.64 60.50
Price to operating profit (P/OP) 19.01 17.53 16.71 28.70 30.74
Price to sales (P/S) 5.34 6.62 5.92 7.86 9.38
Price to book value (P/BV) 3.79 5.07 5.66 8.58 10.53

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Regeneron Pharmaceuticals Inc.’s P/E ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Regeneron Pharmaceuticals Inc.’s P/OP ratio increased from 2017 to 2018 and from 2018 to 2019.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Regeneron Pharmaceuticals Inc.’s P/S ratio increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Regeneron Pharmaceuticals Inc.’s P/BV ratio decreased from 2017 to 2018 and from 2018 to 2019.

Price to Earnings (P/E)

Regeneron Pharmaceuticals Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 110,019,809 109,277,189 107,696,798 106,080,755 104,788,145
Selected Financial Data (US$)
Net income (in thousands) 2,115,800  2,444,400  1,198,511  895,522  636,056 
Earnings per share (EPS)2 19.23 22.37 11.13 8.44 6.07
Share price1, 3 381.87 406.46 322.62 360.00 367.24
Valuation Ratio
P/E ratio4 19.86 18.17 28.99 42.64 60.50
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 41.83 56.47 220.29 55.16 12.83
AbbVie Inc. 17.82 20.60 35.47 16.54 17.01
Amgen Inc. 17.07 14.01 64.06 16.03 15.95
Biogen Inc. 9.97 14.79 28.83 15.41 16.67
Bristol-Myers Squibb Co. 41.99 16.81 103.55 20.56 64.22
Eli Lilly & Co. 16.19 39.13 32.39 33.35
Gilead Sciences Inc. 16.45 15.26 22.75 6.83 6.75
Illumina Inc. 43.43 52.00 44.63 52.01 50.07
Johnson & Johnson 25.99 23.74 268.10 20.08 18.80
Merck & Co. Inc. 20.60 33.46 61.63 46.14 31.64
Pfizer Inc. 11.63 21.58 9.99 28.10 26.37
Vertex Pharmaceuticals Inc. 52.90 22.59 155.08
Zoetis Inc. 45.89 28.68 44.09 31.63 62.14
P/E Ratio, Sector
Pharmaceuticals & Biotechnology 20.75 23.18 37.52 21.01 19.11
P/E Ratio, Industry
Health Care 22.68 25.04 35.39 22.63 20.66

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
EPS = Net income ÷ No. shares of common stock outstanding
= 2,115,800,000 ÷ 110,019,809 = 19.23

3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.

4 2019 Calculation
P/E ratio = Share price ÷ EPS
= 381.87 ÷ 19.23 = 19.86

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Regeneron Pharmaceuticals Inc.’s P/E ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019.

Price to Operating Profit (P/OP)

Regeneron Pharmaceuticals Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 110,019,809 109,277,189 107,696,798 106,080,755 104,788,145
Selected Financial Data (US$)
Income from operations (in thousands) 2,209,800  2,534,400  2,079,591  1,330,741  1,251,916 
Operating profit per share2 20.09 23.19 19.31 12.54 11.95
Share price1, 3 381.87 406.46 322.62 360.00 367.24
Valuation Ratio
P/OP ratio4 19.01 17.53 16.71 28.70 30.74
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 34.03 36.64 60.88 24.25 19.80
AbbVie Inc. 10.82 18.35 19.63 10.49 11.61
Amgen Inc. 13.84 11.46 12.71 12.64 13.07
Biogen Inc. 8.34 11.13 13.70 11.08 12.09
Bristol-Myers Squibb Co. 24.42 16.16 28.87 19.79 53.18
Eli Lilly & Co. 27.08 33.99 39.61 25.63 29.86
Gilead Sciences Inc. 20.66 10.15 7.45 5.23 5.50
Illumina Inc. 44.17 48.64 53.47 40.99 37.71
Johnson & Johnson 19.83 18.34 18.94 16.09 16.50
Merck & Co. Inc. 17.47 25.08 22.58 33.62 20.29
Pfizer Inc. 14.36 17.19 15.62 16.88 15.52
Vertex Pharmaceuticals Inc. 51.98 74.57 331.55 2,143.58
Zoetis Inc. 35.00 22.59 22.33 18.65 28.09
P/OP Ratio, Sector
Pharmaceuticals & Biotechnology 18.50 18.80 18.34 15.37 14.99
P/OP Ratio, Industry
Health Care 19.85 19.64 19.08 16.21 15.76

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 2,209,800,000 ÷ 110,019,809 = 20.09

3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.

4 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 381.87 ÷ 20.09 = 19.01

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Regeneron Pharmaceuticals Inc.’s P/OP ratio increased from 2017 to 2018 and from 2018 to 2019.

Price to Sales (P/S)

Regeneron Pharmaceuticals Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 110,019,809 109,277,189 107,696,798 106,080,755 104,788,145
Selected Financial Data (US$)
Revenues (in thousands) 7,863,400  6,710,800  5,872,227  4,860,427  4,103,728 
Sales per share2 71.47 61.41 54.53 45.82 39.16
Share price1, 3 381.87 406.46 322.62 360.00 367.24
Valuation Ratio
P/S ratio4 5.34 6.62 5.92 7.86 9.38
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.83 4.37 3.84 3.70 2.78
AbbVie Inc. 4.22 3.58 6.67 3.84 3.83
Amgen Inc. 6.03 5.22 5.82 5.65 5.28
Biogen Inc. 4.08 4.87 5.96 4.98 5.49
Bristol-Myers Squibb Co. 5.52 3.67 5.02 4.72 6.07
Eli Lilly & Co. 6.03 5.15 3.71 4.18 4.02
Gilead Sciences Inc. 4.00 3.84 4.10 3.08 3.80
Illumina Inc. 12.28 12.89 11.77 10.03 10.41
Johnson & Johnson 4.79 4.45 4.56 4.62 4.13
Merck & Co. Inc. 4.33 4.92 3.68 4.54 3.56
Pfizer Inc. 3.66 4.49 4.05 3.84 3.76
Vertex Pharmaceuticals Inc. 14.95 15.54 16.42 12.51 20.38
Zoetis Inc. 11.00 7.03 7.18 5.31 4.42
P/S Ratio, Sector
Pharmaceuticals & Biotechnology 4.95 4.70 4.77 4.42 4.25
P/S Ratio, Industry
Health Care 3.82 3.59 3.60 3.26 3.19

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 7,863,400,000 ÷ 110,019,809 = 71.47

3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.

4 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 381.87 ÷ 71.47 = 5.34

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Regeneron Pharmaceuticals Inc.’s P/S ratio increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.

Price to Book Value (P/BV)

Regeneron Pharmaceuticals Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 110,019,809 109,277,189 107,696,798 106,080,755 104,788,145
Selected Financial Data (US$)
Stockholders’ equity (in thousands) 11,089,700  8,757,300  6,144,078  4,449,245  3,654,837 
Book value per share (BVPS)2 100.80 80.14 57.05 41.94 34.88
Share price1, 3 381.87 406.46 322.62 360.00 367.24
Valuation Ratio
P/BV ratio4 3.79 5.07 5.66 8.58 10.53
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 4.96 4.38 3.40 3.76 2.68
AbbVie Inc. 36.95 21.24 22.17
Amgen Inc. 13.84 9.41 5.02 4.14 3.94
Biogen Inc. 4.40 5.03 5.80 4.70 6.31
Bristol-Myers Squibb Co. 2.80 5.89 8.88 5.66 7.04
Eli Lilly & Co. 51.67 12.87 7.33 6.33 5.51
Gilead Sciences Inc. 3.93 3.89 5.15 4.88 6.59
Illumina Inc. 9.43 11.43 11.79 10.95 12.50
Johnson & Johnson 6.61 6.08 5.79 4.72 4.07
Merck & Co. Inc. 7.83 7.79 4.30 4.51 3.15
Pfizer Inc. 3.00 3.80 2.98 3.40 2.84
Vertex Pharmaceuticals Inc. 10.23 10.68 20.14 18.42 22.38
Zoetis Inc. 25.42 18.74 21.52 17.46 19.72
P/BV Ratio, Sector
Pharmaceuticals & Biotechnology 6.28 6.55 5.55 4.92 4.48
P/BV Ratio, Industry
Health Care 5.41 5.41 4.87 4.33 3.90

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 11,089,700,000 ÷ 110,019,809 = 100.80

3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.

4 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 381.87 ÷ 100.80 = 3.79

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Regeneron Pharmaceuticals Inc.’s P/BV ratio decreased from 2017 to 2018 and from 2018 to 2019.